medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Número S2

<< Anterior Siguiente >>

Ann Hepatol 2011; 10 (S2)


Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure

Pérez HJL, Higuera TF, Serralde-Zúńiga AE, Abdo FJM

Idioma: Ingles.
Referencias bibliográficas: 16
Paginas: 66-69
Archivo PDF: 41.36 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gitlin N. Hepatic encephalopathy. In: Zakim D Boyer TD (eds.). Hepatology: a textbook of liver disease. Vol. 1. 3rd. Ed. Philadelphia: W.B. Saunders; 1996, p. 605-17.

  2. Blei AT, Cordoba H. Practice Parameters Committee of the American College of Gastroenterology. Hepa tic encephalopathy. Am J Gastroenterol 2001; 96: 1968-76.

  3. Clemmesen JO, Kondrup J, Ott P. Splachnic and leg exchange of amino acids and ammonia in acute liver failure. Gastroenterology 2000; 118: 1131-39.

  4. Lockwood AH, McDonald JM, Reiman RE. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest 1979; 63: 449-60.

  5. Felipo V, Butterworth RF. Neurobiology of ammonia. Progr Neurobiol 2002; 67: 259-79.

  6. Lai JC, Cooper AJ. Brain alpha-ketoglutarate dehydrogenase complex: kinetic properties, regional distribution, and effects of inhibitors. J Neurochem 1986; 47: 1376-86.

  7. Olde DSW, Deutz NE, Dejong CH, Soeters PB, Jalan R. Interorgan ammonia metabolism in liver failure. Neurochem Int 2002; 41: 177-88.

  8. Haussinger D. Regulation of hepatic ammonia metabolism: the intercellular glutamine cycle. Adv Enzyme Regul 1986; 25: 159-80.

  9. Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmuller E, Holm E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 1993; 19: 424-30.

  10. Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF. L-ornithine L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 1999; 30: 636-40.

  11. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmer R, et al. Therapeutic efficacy of L-ornithine L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, doubleblind study. Hepatology 1997; 25: 1351-60.

  12. Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmüller E, Holm E. Effects of L-ornithine L-aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 1993; 19: 424-30.

  13. Kircheis G, Wettstein M, Dahl S, Häussinger D. Clinical efficacy of L-ornithine L-aspartate in the management of hepatic encephalopathy. Metab Brain Disease 2002; 17: 453-62.

  14. Ahmad I, Khan AA, Alam A, Dilshad A, Butt AK, Shafqat F, et al. L-ornithine L-aspartate infusion efficacy in hepatic encephalopathy. J Coll Physicians Surg Pak 2008; 18: 684-87.

  15. Acharya SK, Bhatia V, Sreenivas V, Khanal S. Efficacy of L-ornithine L-aspartate in acute liver failure: a doubleblind, randomized, placebo-controlled study. Gastroenterology 2009; 136: 2159-68.

  16. Abdo-Francis JM, Pérez HJL, Hinojosa RA, Hernández-Vásquez J. Use of L-ornitin L-aspartate (LOLA) reduce time of hospital stay in patients with hepatic encephalopathy. Rev Gastroenterol Mex 2010; 75(2): 135-41.




2020     |     www.medigraphic.com